Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile

Vaccine

Volumn 13, Issue 9, 1995, Pages 821-829

  Boslego, J ^a   Garcia, J ^b   Cruz, C ^c   Zollinger, W ^a   Brandt, B ^a   Ruiz, S ^b   Martinez, M ^c   Arthur, J ^a   Underwood, P ^a   Silva, W ^b   Moran, E ^a   Hankins, W ^d   Gilly, J ^d   Mays, J ^d   the Chilean National Committee for Meningococcal Disease, ^e  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b INSTITUTO DE SALUD PÚBLICA DE CHILE   (Chile)

^c Ministerio de Salud de Chile   (Chile)

^d Connaught Laboratories Inc ^*  (United States)

^e NONE

Author keywords

efficacy trial; Neisseria meningitidis; noncovalent complex; vaccine

Indexed keywords

IMMUNOGLOBULIN G; MENINGOCOCCUS VACCINE;

ADOLESCENT; ADULT; ANTIBODY RESPONSE; ARTICLE; CHILD; CHILE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENINGOCOCCOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL VACCINES; BLOTTING, WESTERN; CHILD; CHILD, PRESCHOOL; CHILE; COMPLEMENT SYSTEM PROTEINS; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INFANT; MALE; MENINGITIS; NEISSERIA MENINGITIDIS; PHARYNX; PORINS; PROSPECTIVE STUDIES;

EID: 0029069384     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0264-410X(94)00037-N     Document Type: Article

References (28)

1. Immunologic response of man to group B polysaccharide vaccines
2. Enhancement of immunological activity by noncovalent complexing of meningococcal Group B polysaccharide and outer membrane proteins
3. Immunogenicity in adult males of a Neisseria meningitidis group B vaccine composed of polysaccharide complexed with outer membrane proteins
4. Measurement of antibodies to meningococcal group B polysaccharide: low avidity binding and equilibrium binding constants
5. Importance of complement source in bactericidal activity of human antibody and murine monoclonal antibody to meningococci
6. Induction of meningococcal group B polysaccharide specific immunoglobulin G antibodies in mice by using an N propionylated B polysaccharide-tetanus toxoid conjugate vaccine
7. Antibodies to poly((2→8)-alpha-N-acetylneuraminic acid) and poly((2→9)-alpha-N-acetylneuraminic acid) are elicited by immunization of mice with Escherichia coli K92 conjugates potential vaccines for groups B and C meningococci and E coli K1
8. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis
9. A proposed nomenclature for designation of serotypes within Neisseria meningitis
10. Intercontinental spread of a genetically distinctive complex of clones of Neisseria meningitis causing epidemic disease
11. A complex of N. meningitidis group B polysaccharide and type 2 outer membrane protein immunogenic in man
12. Immunogenicity and clinical evaluation of group B Neisseria meningitidis outer membrane protein vaccines
13. New and improved vaccines against meningococcal disease
14. Development and evaluation of group B protein vaccines: report of a group B field trial
15. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway
16. Efficacy evaluation of the Cuban vaccine VA-MENGOC-BC against disease caused by serogroup B Neisseria meningitidis
17. Serotype-specific outbreak of group B meningococcal disease in Iquique, Chile
18. Immune response to Neisseria meningitidis
19. A general approach to standardization of the solid phase radioimmunoassay for quantitation of class-specific antibodies
20. Cleavage of structural proteins during the assembly of the head of bacteriophage T4
21. Purification and characterization of H. 8 antigen from group B Neisseria meningitidis
22. Serotyping and subtyping of Neisseria meningitidis isolates by coagglutination, dot-blotting and ELISA
23. A family of confidence intervals for the ratio of two binomial proportions
24. Protective efficacy of a serogroup B Meningococcal vaccine in Sao Paulo, Brazil
25. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba
26. Production, characterization and control of MenB-Vaccine «Folkehelsaå: an outer membrane vesicle vaccine against group B meningococcal disease
27. Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age